




Supplementary data for the article: 
 
 
 Tadić, A.; Poljarević, J.; Krstić, M.; Kajzerberger, M.; Aranelović, S.; Radulović, S.; 
Kakoulidou, C.; Papadopoulos, A. N.; Psomas, G.; Grgurić-Šipka, S. Ruthenium-Arene 
Complexes with NSAIDs: Synthesis, Characterization and Bioactivity. New Journal of 
Chemistry 2018, 42 (4), 3001–3019. https://doi.org/10.1039/c7nj04416j  
 
Ruthenium-arene complexes with NSAIDs: Synthesis, characterization and bioactivity 
 
Ana Tadić,a Jelena Poljarević,a Milena Krstić,b Marijana Kajzerberger,c Sandra 
Aranđelović,c Siniša Radulović,c Chrisoula Kakoulidou,d Athanasios N. Papadopoulos,e 
George Psomas,d Sanja Grgurić-Šipkaa 
 
a Faculty of Chemistry, University of Belgrade, Studentski trg 12-16, 11000 Belgrade, Serbia 
b Faculty of Veterinary Medicine, University of Belgrade, Bulevar oslobodjenja 18, 11000 
Belgrade, Serbia 
c Institute for Oncology and Radiology of Serbia, Pasterova 14, 11000 Belgrade, Serbia 
d Department of General and Inorganic Chemistry, Faculty of Chemistry, Aristotle University of 
Thessaloniki, P.O. Box 135, GR-54124 Thessaloniki, Greece. 
e Department of Nutrition and Dietetics, Faculty of Food Technology and Nutrition, Alexandrion 




S1. NMR spectra of synthesized complexes 
 
 
Electronic Supplementary Material (ESI) for New Journal of Chemistry.
This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2018
Figure S1. Parallel 1H NMR spectra of ligand1 and complex 1 
 
 
Figure S2. Parallel 13C NMR spectra of  ligand 1 and complex 1 
 
 Figure S3. Parallel 1H NMR spectra of ligand 2 and complex 2 
 
Figure S4. Parallel 13C NMR spectra of ligand 2 and complex 2 
  
Figure S5. Parallel 1H NMR spectra of ligand1 and complex 3 
 
 Figure S6. Parallel 13C NMR spectra of  ligand 1 and complex 3 
 
 
 Figure S7. Parallel 1H NMR spectra of ligand 2  and complex 4 
 
 






S2. MTT assay 
 
Table 1. IC50 [µM] values obtained after 72 h of continuous drug action. 
Compound K562 A549 MDA-MB-231 MRC-5 *SI K562 *SI A549 *SIMDA-MB-231 
1 11.9±4.4 45.5±2.7 22±3.6 39.6±3.7 3.33 0.87 1.80 
2 96.4±2 145.1±6.4 153±1.2 222.6±23.9 2.31 1.53 1.45 
3 13.2±6.2 31.7±1.15 26±1.7 42±1.3 3.18 1.32 1.62 
4 133±7 142.4±9.3 121.4±1.8 275.7±14.5 2.07 1.94 2.27 
Hindo 155.9±11.4 161.5±13.9 244.7±17.8 230.5±17.8 1.48 1.43 0.94 
Hmef 143.9±4.1 217.3±46.7 237.9±18.8 >300 >2.08 >1.38 >1.26 
CDDP 10.3±1.2 13.6±1.8 15.9±2.1 9.3±0.9 0.90 0.68 0.58 
 
* IC50 [µM] values are presented as the mean ± SEM of three independent experiments. > 300 
denotes that IC50 was not obtained in the range of concentrations tested up to 300 µM.  
*SI-selectivity index for tested complexes, ligands and cisplatin, in tumor cell lines (K562, A549 
and MDA-MB-231), related to non-tumor MRC-5 cell line: SIK562 (IC50 MRC-5/IC50 K562), SIA549 
(IC50 MRC-5/IC50 A549), SIMDA-MB-231(IC50 MRC-5/IC50 MDA-MB-231). SI values for tested 




S3. Interaction with biomolecules 
 
S3-1. Interaction with serum albumins 










  (eq. S1) 
where Icorr = corrected intensity, Imeas = the measured intensity, c = the concentration of the 
quencher, d = the cuvette (1 cm), ε(λexc) and ε(λem) = the ε of the quencher at the excitation and the 
emission wavelength, respectively, as calculated from the UV-vis spectra of the complexes.1 
The Stern-Volmer and Scatchard graphs are used in order to study the interaction of a 





   (eq. S2) 
where Io = the initial tryptophan fluorescence intensity of SA, I = the tryptophan fluorescence 
intensity of SA after the addition of the quencher (i.e. complexes 1-4), kq = the quenching constant, 
KSV = the Stern-Volmer constant, τo = the average lifetime of SA without the quencher, [Q] = the 
concentration of the quencher) KSV (in M
-1) can be obtained by the slope of the diagram Io/I versus 
[Q], and subsequently the quenching constant (kq, in M
-1s-1) is calculated from eq. S3, with τo= 10-8 
s as fluorescence lifetime of tryptophan in SA,  
KSV = kqτo  (eq. S3) 









  (eq. S4) 
where n is the number of binding sites per albumin and K is the SA-binding constant, K (in M-1) is 
calculated from the slope in plots (ΔI/Io)/[Q] versus ΔI/Io and n is given by the ratio of y intercept 
to the slope.3 
 
S3-2. Interaction with CT DNA 
The DNA-binding constant (Kb, in M
-1) can be obtained by monitoring the changes in the 
absorbance at the corresponding λmax with increasing concentrations of CT DNA and it is given by 













  (eq. S5) 
where [DNA] is the concentration of DNA in base pairs, εA = Aobsd/[compound], εf = the extinction 
coefficient for the free compound and εb = the extinction coefficient for the compound in the fully 
bound form. 
 
S3-3. Competitive studies with EB 
The Stern-Volmer constant (KSV, in M
-1) is used to evaluate the quenching efficiency for 
each compound according to the Stern-Volmer equation (eq. S2),2 where Io and I are the emission 
intensities of the EB-DNA solution in the absence and the presence of the quencher, respectively, 
[Q] is the concentration of the quencher (i.e. complexes 1-4), τo = the average lifetime of the 
emitting system without the quencher and kq = the quenching constant. KSV may be obtained from 
the Stern-Volmer plots by the slope of the diagram Io/I versus [Q]. Taking τo = 23 ns as the 
fluorescence lifetime of the EB-DNA system,5 the quenching constants (kq, in M
-1s-1) of the 
compounds can be determined according to eq. (S3).  
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Table S2. The BSA and HSA binding constants and parameters (Ksv, kq, K, n) for complexes 1-4. 
Compound Ksv (M-1) kq (M-1s-1) K (M-1) n 
BSA     
K[Ru(η6-p-cymene)(indo)Cl2], 1 1.25(±0.05)×105 1.25(±0.05)×1013 4.49(±0.30)×105 0.68 
(NH4)[Ru(η6-p-cymene)(mef)Cl2], 2 1.70(±0.08)×105 1.70(±0.08)×1013 3.63(±0.15)×105 0.86 
K[Ru(η6-p-toluene)(indo)Cl2], 3 4.85(±0.11)×104 4.85(±0.11)×1012 5.30(±0.18)×104 0.96 
(NH4)[Ru(η6-p-toluene)(mef)Cl2], 4 1.30(±0.04)×105 1.30(±0.04)×1013 2.63(±0.10)×105 0.84 
HSA     
K[Ru(η6-p-cymene)(indo)Cl2], 1 6.10(±0.29)×104 6.10(±0.29)×1012 2.15(±0.08)×105 0.57 
(NH4)[Ru(η6-p-cymene)(mef)Cl2], 2 5.46(±0.19)×104 5.46(±0.19)×1012 9.79(±0.34)×104 0.78 
K[Ru(η6-p-toluene)(indo)Cl2], 3 2.04(±0.13)×104 2.04(±0.13)×1012 9.44(±0.40)×104 0.31 
(NH4)[Ru(η6-p-toluene)(mef)Cl2], 4 4.32(±0.29)×104 4.32(±0.29)×1012 4.24(±0.12)×105 0.37 
 
  












































Figure S9. Stern-Volmer quenching plot of HSA for complexes (A)-(D) 1-4, respectively. 
 
  
















































Figure S10. Stern-Volmer quenching plot of BSA for complexes (A)-(D) 1-4, respectively. 
 
  

























































Figure S11. Scatchard plot of HSA for complexes (A)-(D) 1-4, respectively. 
 
  























































Figure S12. Scatchard plot of BSA for complexes (A)-(D) 1-4, respectively. 
 
  






















































































































Figure S13. Plot of [DNA]/(εA-εf)  vs [DNA] for complexes (A)-(D) 1-4, respectively. 
 
  















































Figure S14. Stern-Volmer quenching plot of EB-DNA fluorescence for complexes (A)-(D) 1-4, 
respectively. 
 
 
